Table 2.
Vaccine effectiveness against SARS-CoV-2 infection of any severity up to 9 months after full vaccination (>14 days after the second dose) by number of days after the second dose
| Number of individuals |
Vaccinated |
Unvaccinated |
Vaccine effectiveness (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|
| Number of events | Incidence per 100 000 person-days | Number of events | Incidence per 100 000 person-days | Adjusted for age and baseline date | Fully adjusted* | |||
| Total study cohort (any vaccine) | 1 685 948 | 6147 | 4·9 | 21 771 | 31·6 | 84% (83 to 84) | 84% (83 to 84) | |
| 15–30 days | 1 685 948 | 397 | 1·6 | 4719 | 19·5 | 92% (91 to 93) | 92% (91 to 93) | |
| 31–60 days | 1 544 326 | 1254 | 2·5 | 8908 | 22·5 | 89% (88 to 90) | 89% (88 to 89) | |
| 61–120 days | 1 363 616 | 2436 | 2·6 | 7522 | 14·4 | 83% (82 to 83) | 82% (81 to 83) | |
| 121–180 days | 635 402 | 820 | 1·0 | 399 | 1·8 | 52% (46 to 58) | 48% (41 to 54) | |
| 181–210 days | 327 257 | 718 | 1·2 | 161 | 2·1 | 42% (31 to 51) | 32% (19 to 43) | |
| >210 days | 239 822 | 522 | 1·0 | 62 | 1·2 | 23% (0 to 41) | 23% (−2 to 41) | |
| BNT162b2 subcohort | 1 274 214 | 5062 | 5·1 | 19 121 | 36·4 | 84% (84 to 85) | 85% (84 to 85) | |
| 15–30 days | 1 274 214 | 333 | 1·7 | 4039 | 22·1 | 92% (91 to 93) | 92% (92 to 93) | |
| 31–60 days | 1 166 247 | 1095 | 2·9 | 7982 | 26·7 | 89% (88 to 90) | 89% (88 to 90) | |
| 61–120 days | 1 032 971 | 1796 | 2·6 | 6601 | 16·6 | 85% (84 to 85) | 84% (84 to 85) | |
| 121–180 days | 480 153 | 631 | 1·0 | 292 | 1·7 | 52% (45 to 58) | 47% (39 to 55) | |
| 181–210 days | 304 298 | 688 | 1·2 | 145 | 2·1 | 39% (26 to 49) | 29% (15 to 41) | |
| >210 days | 231 006 | 519 | 1·1 | 62 | 1·3 | 23% (1 to 41) | 23% (−2 to 41) | |
| mRNA-1273 subcohort | 153 760 | 300 | 2·9 | 1722 | 28·2 | 89% (88 to 91) | 89% (88 to 90) | |
| 15–30 days | 153 760 | 20 | 0·9 | 493 | 22·5 | 96% (94 to 98) | 96% (94 to 97) | |
| 31–60 days | 139 532 | 67 | 1·5 | 743 | 21·1 | 93% (91 to 95) | 93% (90 to 94) | |
| 61–120 days | 123 610 | 116 | 1·4 | 418 | 9·0 | 86% (82 to 88) | 85% (82 to 88) | |
| 121–180 days | 52 254 | 65 | 1·0 | 53 | 2·6 | 72% (59 to 80) | 71% (56 to 80) | |
| >180 days | 22 755 | 32 | 0·8 | 15 | 2·4 | 69% (44 to 83) | 59% (18 to 79) | |
| ChAdOx1 nCoV-19 subcohort | 153 194 | 465 | 5·0 | 469 | 7·2 | 49% (42 to 55) | 44% (36 to 52) | |
| 15–30 days | 153 194 | 33 | 1·4 | 93 | 4·2 | 66% (50 to 77) | 68% (52 to 79) | |
| 31–60 days | 144 772 | 53 | 1·2 | 88 | 2·3 | 55% (36 to 68) | 49% (28 to 64) | |
| 61–120 days | 129 103 | 293 | 3·5 | 262 | 4·9 | 48% (39 to 56) | 41% (29 to 51) | |
| >120 days | 53 060 | 86 | 1·6 | 26 | 1·4 | 0% (−55 to 36) | −19% (−98 to 28) | |
| ChAdOx1 nCoV-19 and an mRNA vaccine† subcohort | 103 532 | 316 | 4·8 | 442 | 11·8 | 68% (63 to 72) | 65% (58 to 70) | |
| 15–30 days | 103 532 | 11 | 0·7 | 92 | 6·2 | 89% (79 to 94) | 89% (79 to 94) | |
| 31–60 days | 92 623 | 37 | 1·2 | 88 | 4·0 | 74% (62 to 82) | 72% (59 to 82) | |
| 61–120 days | 76 924 | 230 | 3·8 | 234 | 8·8 | 63% (55 to 69) | 55% (45 to 64) | |
| >120 days | 49 664 | 38 | 0·8 | 28 | 1·8 | 61% (36 to 76) | 66% (41 to 80) | |
*
Adjusted for age, baseline date, sex, homemaker service, place of birth, education, and comorbidities at baseline.
†
The mRNA vaccine was either BNT162b2 or mRNA-1273.